News Posts List
ATLANTA—Dr. Sang-Moo Kang, professor in the Institute for Biomedical Sciences at Georgia State University, has renewed a four-year, $1.9 million federal grant to develop influenza vaccines that offer enhanced protection against a broad range of influenza virus strains.
Thermo Scientific Pharma mini implant line is an automated, integrated system designed for continuous production of drug implants
NP10679 is in development to prevent brain ischemia during stroke or subarachnoid hemorrhage
Skin Vaccination with Microneedle Patch, Influenza Fusion Protein Improves Efficacy of Seasonal Flu Vaccines, Study Finds
ATLANTA—A boosting skin vaccination with a biodegradable microneedle patch and protein constructed from sequences of influenza virus subtypes could improve the effectiveness of conventional influenza vaccines, according to a study led by Georgia State University.
Atlanta-based Tech Square Labs Fund has received a $1 million investment from Invest Georgia, a state-run venture capital fund.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker regarding the planned vote in the U.S. House on the FDA Reauthorization Act of 2017:
Dune Medical Devices, a metro Philadelphia-based company dedicated to identifying microscopic residual cancer, is moving its U.S. headquarters to Atlanta.
BIO Adopts Principles on Workplace Development, Diversity, and Inclusion; Launches Board WDDI Commit
WASHINGTON--(BUSINESS WIRE)--Today, the Biotechnology Innovation Organization (BIO) released a set of principles on workforce development, diversity, and inclusion (WDDI) for the biotechnology industry. Concurrent with the adoption of these principles, BIO established a board-level WDDI Committee charged with working to foster workforce development, diversity, and inclusion at BIO and throughout the biotech industry. The Committee will be chaired by Helen Torley, President & CEO of Halozyme, who is succeeding Julie Gerberding, Executive Vice President & Chief Patient Officer at Merck, who led the Committee as it developed BIO’s WDDI principles over the last year.
Breaking all previous records, BIO 2017 hosted over 41,400 partnering meetings during this year’s event. Facilitated by BIO’s unique One-on-One Partnering™ system, these invaluable connections form the foundation of innovative industry collaborations and scientific breakthroughs. That word—breakthrough—was heard and seen throughout the Convention Center in San Diego from June 19 – 22. “Breakthrough” reflects the innovation and exciting advancement in the biotech sector.
Can we combat disease threats before they even emerge? In the fight against infectious diseases, understanding where outbreaks are most likely to happen and under which circumstances can help us develop tools to address risk to potentially prevent the next pandemic.
|Neon CRM by Neon One|